Different targeted therapies are available for BC, depending on the tumor subtype: estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer (TNBC) (Polyak and Metzger Filho, 2012). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.